MLN8054, a selective inhibitor of Aurora A kinase: final results of a phase I clinical trial

被引：1
|
作者：
Cervantes, A. [1 ]
Macarulla, T. [2 ]
Rosello, S. [1 ]
Rodriguez-Braun, E. [1 ]
Baselga, J. [2 ]
Tabernero, J. [2 ]
Liu, H. [5 ]
Chakravarty, A. [3 ]
Bowman, D. [4 ]
Eton, O. [6 ]
机构：
[1] Hosp Clin Univ Valencia, Valencia, Spain
[2] Vall Hebron Univ Hosp, Barcelona, Spain
[3] Millennium Pharmaceut Inc, Canc Pharmacol, Cambridge, MA USA
[4] Millennium Pharmaceut Inc, Mol & Cellular Oncol, Cambridge, MA USA
[5] Millennium Pharmaceut Inc, Biostat, Cambridge, MA USA
[6] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72213-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：90 / 90
页数：1
相关论文
共 50 条
  • [41] Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia
    Foran, J. M.
    Ravandi, F.
    O'Brien, S. M.
    Borthakur, G.
    Rios, M.
    Boone, P.
    Worrell, J.
    Mallett, K. H.
    Squires, M.
    Fazal, L. H.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Phase 1 study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States
    Infante, J.
    Dees, E. C.
    Cohen, R. B.
    Burris, H.
    O'Neil, B.
    Murphy, P.
    Lee, Y.
    Pappas, J.
    Ecsedy, J. A.
    Eton, O.
    EJC SUPPLEMENTS, 2008, 6 (12): : 90 - 91
  • [43] A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer.
    Beltran, Himisha
    Rubin, Mark A.
    Mosquera, Juan Miguel
    Christos, Paul J.
    Calukovic, Olivera
    Karpenko, Irene
    Pinski, Jacek K.
    Danila, Daniel Costin
    Nanus, David M.
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors
    Cervantes-Ruiperez, A.
    Elez, M. E.
    Rosello, S.
    Macarulla, T.
    Rodriguez-Braun, E.
    Lee, Y.
    Ecsedy, J.
    Liu, H.
    Fingert, H.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients.
    Rubin, E. H.
    Shapiro, G. I.
    Stein, M. N.
    Watson, P.
    Bergstrom, D.
    Xiao, A.
    Clark, J. B.
    Freedman, S. J.
    Eder, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 123S - 123S
  • [46] A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients
    Robert, F.
    Verschraegen, C.
    Hurwitz, H.
    Uronis, H.
    Advani, R.
    Chen, A.
    Taverna, P.
    Wollman, M.
    Fox, J.
    Michelson, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] STM-01: Phase I EFFTox study of aurora A kinase inhibitor alisertib (MLN8237) given in combination with selective VEGFR inhibitor pazopanib for therapy of solid tumors.
    Dudek, Arkadiusz Z.
    Unal, Imran
    Xie, Hui
    Feldman, Lawrence Eric
    Venepalli, Neeta K.
    Danciu, Oana Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] STM-01: Phase I EffTox study of aurora A kinase inhibitor alisertib (MLN8237) given in combination with selective VEGFR inhibitor pazopanib for therapy of solid tumors.
    Shah, Hirai A.
    Christian, Sonia
    Ahmed, Bilawal
    Chowdhery, Rozina A.
    Venepalli, Neeta K.
    Danciu, Oana Cristina
    Dudek, Arkadiusz Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia
    Vormoor, B.
    Veal, G. J.
    Griffin, M. J.
    Boddy, A. V.
    Irving, J.
    Minto, L.
    Case, M.
    Banerji, U.
    Swales, K. E.
    Tall, J. R.
    Moore, A. S.
    Toguchi, M.
    Acton, G.
    Dyer, K.
    Schwab, C.
    Harrison, C. J.
    Grainger, J. D.
    Lancaster, D.
    Kearns, P.
    Hargrave, D.
    Vormoor, J.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (06)
  • [50] Pharmacokinetic (PK) and pharmacodynamic (PD) results from two phase I studies of the investigational selective Aurora A kinase (AAK) inhibitor MLN8237: Exposure-dependent AAK inhibition in human tumors.
    Cervantes-Ruiperez, A.
    Burris, H. A., III
    Cohen, R. B.
    Dees, E. C.
    Infante, J. R.
    Fingert, H. J.
    Shinde, V.
    Venkatakrishnan, K.
    Chakravarty, A.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345